September 24th is World Cancer Research Day.
American Society of Clinical Oncology (ASCO)calls upon to continue and heighten
research in areas of cancer prevention and treatment, along with discovering
new drugs. World Cancer Research Day is a global initiative that aims to raise
awareness about the critical importance of cancer research.
It is estimated that by 2030 cancer
will be the leading cause of death worldwide with new cases expected to
increase to 21.6 million each year. According to the GLOBOCAN report, in 2012
there were 14 million new cases diagnosed and 8.2 million cancer-related deaths
worldwide.
Life years and productivity loss,
together with disabilities resulting from cancer account for the largest economic
cost on a global scale, compared to other causes of death including
infectious diseases.
One of the most important areas is to
support and promote research on the causes, prevention and early detection of
cancer as a key element in controlling the disease. This will lead us towards
the discovery of a cure for cancer or transforming the disease into a chronic
illness, both approaches translating into higher survival rates.
Some of the important research paper on
Obstetrics and Gynecological cancer published recently are:
USPSTF simplifies cervical cancer
screening recommendations: Dual testing no longer advised
The US Preventive Services Task Force
(USPSTF) has issued new draft recommendations for cervical cancer
screening with a major change that it recommends either cervical cytology (CC)
or high-risk HPV (hrHPV) test as a screening procedure every 3 years for women
aged 30-65 years, and not both ( Grade A)
Magseed, a minimally invasive breast
marker for cancer localization during surgery receives clearance in Europe
Endomag, a
surgical guidance company received CE clearance for Sentimag+Magseed breast
cancer diagnostic system, that guides surgeon for precise location of impalpable
tumor during breast lumpectomy. It improves outcome and reduces the amount of
radioactive exposure for patients.
FDA clears first 2D digital
mammography system that allows patients to control the compression
GE Healthcare announced today FDA 510(k) clearance of an industry-first, patient-assisted
mammography system, Senographe Pristina Duetathat makes mammography experience
more comfortable by putting the control in patients’ own hands.
FDA approves world’s first pioneering
gene therapy for cancer
The U.S.Food and Drug Administration in its landmark
and historic action today approved the world’s first gene therapy, Novartis'
Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with
a form of acute lymphoblastic leukemia (ALL).
This opens a new frontier in treatment
of cancer and other serious and life-threatening diseases.
Are you dense? What every woman and
her healthcare provider needs to know.
Nearly 20 plus years of research have
provided sufficient evidence to link dense breast tissue and increased risk of
missing cancer diagnosis by screening mammography. As the breast density
increases, the reliability of mammogram as a screening tool for picking up
breast malignancy decreases.
What is meant by “being dense”? Breast
density does not correlate with physically palpated firmness of breast, it is a
radiologic finding and cannot be predicted without obtaining a mammogram.
Now Ovarian Tissue paper to support
normal hormonal production: Breakthrough in Regenerative Medicine
An accidental Spill has sparked a
breakthrough in the field of regenerative medidicne. Scientists and engineers
at the Northwestern Medicine have invented a range of bioactive “tissue papers”
made from organs combined with a polymer to make them so pliable.
These new “tissue papers” are so thin
and pliable that they can be folded into an origami bird. Their clinical
application is for wound healing and aid in natural hormone production in young
cancer patients.
Adjunct Metformin helps reversal of
atypical endometrial hyperplasia
Adjunct
metformin treatment help reversal of atypical endometrial hyperplasia (AEH) and
improves overall survival in endometrial cancer reports the result of a systematic review and meta-analysis published ahead of
print in Journal of Gynecologic Oncology.
FDA Approves PARP inhibitor Zejula for
treatment of recurrent ovarian cancer.
The U.S.Food
and Drug Administration today approved Zejula (niraparib)
for the maintenance treatment of epithelial ovarian, fallopian tube or primary
peritoneal cancer in adult patients who have already responded well to
platinum-based chemotherapy.
Here is an interesting video about
importance of research on World Cancer Research Day 2017
